ReviewOncoTargets and therapy2016
Current classification, treatment options, and new perspectives in the management of adipocytic sarcomas.
Review in OncoTargets and therapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 72 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
72 citing papers in PubMed, 2 syntheses or guidelines pooled it, 101 citations in OpenAlex.
- Clinical Utility of CDK4/6 Inhibitors in Sarcoma: Successes and Future Challenges.JCO precision oncology · 2022Pooled it
- Meta-Analysis of Hematological Biomarkers as Reliable Indicators of Soft Tissue Sarcoma Prognosis.Frontiers in oncology · 2020Pooled it
- First-Line Anlotinib Treatment for Soft-Tissue Sarcoma in Chemotherapy-Ineligible Patients: An Open-Label, Single-Arm, Phase 2 Clinical Trial.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024Trial
- Characteristics and Outcomes of Patients With Dedifferentiated Liposarcoma in a US Community Setting.Cancer medicine · 2026Observational
- Real-world characterization of patients with advanced or metastatic liposarcoma, including dedifferentiated liposarcoma, in Japan in the MASTER KEY project.Japanese journal of clinical oncology · 2026Article
- Review
- Modern synthetic pathways towards eribulin and its subunits.Beilstein journal of organic chemistry · 2026Review
- Tocilizumab as a novel bridging therapy for surgery in dedifferentiated liposarcoma complicated by paraneoplastic leukemoid reaction, severe anemia, and thrombocytopenia: a case report.Frontiers in oncology · 2026Article
- Retroperitoneal Dedifferentiated Liposarcoma With Penetrating Abscess Formation Secondary to Ileal Invasion: A Case Report.Clinical case reports · 2026Article
- Cutaneous Mass with Indurated Erythema in the Right Popliteal Fossa: A Quiz.Acta dermato-venereologica · 2025Article
- Real-world survival outcomes and MDM2 prevalence in US patients with metastatic dedifferentiated liposarcoma.Future oncology (London, England) · 2025Article
- From benign appearance to malignant truth: a case report of mesenteric dedifferentiated liposarcoma with inflammatory myofibroblastic tumor-like features.Diagnostic pathology · 2025Article
- Giant dedifferentiated liposarcoma of the neck with osteosarcoma and chondrosarcoma components: A case report.Molecular and clinical oncology · 2025Article
- Review
- Challenges and hope: latest research trends in the clinical treatment and prognosis of liposarcoma.Frontiers in pharmacology · 2025Review
- Diagnostic challenges in imaging and immunohistopathological profiles in extraskeletal osteosarcoma.World journal of surgical oncology · 2024Article
- Liposarcoma: A Journey into a Rare Tumor's Epidemiology, Diagnosis, Pathophysiology, and Limitations of Current Therapies.Cancers · 2024Review
- Angiomyxoma coexisting with focal nodular hyperplasia: A case report.Experimental and therapeutic medicine · 2024Article
- Exploring the biological behavior differences between retroperitoneal and non-retroperitoneal liposarcomas.Heliyon · 2024Article
- An overview on liposarcoma subtypes: Genetic alterations and recent advances in therapeutic strategies.Journal of molecular histology · 2024Review
12 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sarcomas are a heterogeneous group of mesenchymal tumors arising from soft tissue or bone, with an uncertain etiology and difficult classification. Soft tissue sarcomas (STSs) account for around 1% of all adult cancers. Till date, more than 50 histologic subtypes have been identified. Adipocyte sarcoma or liposarcoma (LPS) is one of the most common STS subtypes, accounting for 15% of all sarcomas, with an incidence of 24% of all extremity STSs and 45% of all retroperitoneal STSs. The new World Health Organization classification system has divided LPS into four different subgroups: atypical lipomatous tumor/well-differentiated LPS, dedifferentiated LPS, myxoid LPS, and pleomorphic LPS. These lesions can develop at any location and exhibit different aggressive potentials reflecting their morphologic diversity and clinical behavior. Patients affected by LPS should be managed in specialized multidisciplinary cancer centers. Whereas surgical resection is the mainstay of treatment for localized disease, the benefits of adjuvant and neoadjuvant chemotherapy are still unclear. Systemic treatment, particularly chemotherapy, is still limited in metastatic disease. Despite the efforts toward a better understanding of the biology of LPS, the outcome of advanced and metastatic patients remains poor. The advent of targeted therapies may lead to an improvement of treatment options and clinical outcomes. A larger patient enrollment into translational and clinical studies will help increase the knowledge of the biological behavior of LPSs, test new drugs, and introduce new methodological studies, that is, on treatment response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.